It all started with the mission  to improve the life of at least one patient.

We’ve now lost count.

But our mission remains just as personal.

Behind every scan is a story

Many of us at icometrix have seen someone we love lose words, memories, or independence to a brain disorder.

That’s why our mission is personal.

A life interrupted, a family searching for answers, a care team trying to make the right call.

We build technology to bring clarity in those moments. To help clinicians see what matters, and to help patients hold on to who they are.

From university spin-off to global leaders

2011

icometrix was founded as a spin-off from two Belgian universities and hospitals

2014

Initial development of icobrain completed, supported by multiple pharma partnerships – laying the foundation for FDA clearance

2015 - 2016

Achieved CE marking for icobrain, followed by first FDA clearance – enabling commercialization across Europe and launching our US presence

2017

Expanded icobrain to multiple neurological conditions, including Alzheimer's, stroke, and traumatic brain injury

2020

Launched icolung during the COVID-19 pandemic - delivered free AI lung analyses to over 45,000 individuals.

2020

Launched icompanion, a patient-oriented care platform empowering people with MS to track their health and stay connected with their care team

2021

Secured multiple patents for AI-driven medical imaging technologies

2023

icobrain is the first AI-based neuroradiology solution to receive a CPT-III® code assignment from the AMA, based on extensive clinical validation.

2024

icobrain aria became the only FDA-cleared CADe/CADx solution in neuroradiology - meeting the urgent need for ARIA monitoring in Alzheimer’s care

Meet the people who make all of this happen

Guided by world-leading experts

Board of Directors